Sun Life Financial’s Coherus Oncology CHRS Stock Holding History

Sun Life Financial’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,735	Closed	-$35K	–	484
2019 Q3	$35K	Buy	+1,735	New	+$34.7K	0.01%	332

Other funds holding CHRS

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Sun Life Financial's CHRS Position: Q4 2019 in Review

Sun Life Financial sold out of Coherus Oncology (CHRS) in Q4 2019, closing a stake of 1,735 shares — an estimated $35K sold.

Sun Life Financial first reported a position in CHRS in Q3 2019 and held it in 1 quarter. The position peaked at $35K in Q3 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q4 2019.

Sun Life Financial reported no remaining Coherus Oncology position as of Q4 2019 after selling out during the quarter.
Sun Life Financial sold 1,735 Coherus Oncology shares in Q4 2019, an estimated $35K.
Sun Life Financial first reported a position in Coherus Oncology in Q3 2019 and held it in 1 quarter.
Sun Life Financial's Coherus Oncology position peaked at $35K in Q3 2019.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2019.

Based on Sun Life Financial's 13F filing for Q4 2019, filed 10 Feb 2020.